

Clinical Policy: Teriparatide (Forteo)

Reference Number: CP.PHAR.188

Effective Date: 11.15.17

Last Review Date: 02.18

Line of Business: Commercial, Health Insurance Marketplace, Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Teriparatide (Forteo[®]) is a recombinant human parathyroid hormone analog.

FDA Approved Indication(s)

Forteo is indicated:

- For the treatment of postmenopausal women with osteoporosis at high risk for fracture*. In postmenopausal women with osteoporosis, Forteo reduces the risk of vertebral and nonvertebral fractures.
- To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture*
- For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture*

**High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.*

Policy/Criteria

Provider must submit documentation (including such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Forteo is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Osteoporosis (must meet all):

1. Diagnosis of osteoporosis;
2. Age \geq 18 years or documentation of closed epiphyses (e.g., x-ray);
3. Member meets one of the following (a or b):
 - a. Prescribed by or in consultation with one of the following specialists: a gynecologist, endocrinologist, rheumatologist, orthopaedist, or physiatrist for postmenopausal osteoporosis;
 - b. Failure of a 12-month trial of a bisphosphonate (*alendronate is preferred*) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
4. For postmenopausal osteoporosis, failure of Tymlos* at up to maximally indicated doses unless contraindicated or clinically significant adverse effects are experienced;

CLINICAL POLICY

Teriparatide

**Prior authorization is required for Tymlos*

5. Member has not received cumulative therapy on parathyroid hormone (PTH) analogs (e.g., Tymlos, Forteo) that exceeds 2 years;
6. Dose does not exceed 20 mcg per day (1 pen every 28 days).

Approval duration: 6 months (limited to 2 years cumulative use of PTH analogs per lifetime)

B. Other diagnoses/indications

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Osteoporosis (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. Member has not received cumulative therapy on parathyroid hormone (PTH) analogs (e.g., Tymlos, Forteo) that exceeds 2 years;
4. If request is for a dose increase, new dose does not exceed 20 mcg per day (1 pen every 28 days).

Approval duration: 12 months (limited to 2 years cumulative use of PTH analogs per lifetime)

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.**

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

BMD: bone mineral density

FDA: Food and Drug Administration

PTH: parathyroid hormone

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
alendronate (Fosamax [®])	Osteoporosis 10 mg PO QD or 70 mg PO q week Glucocorticoid-induced osteoporosis 5 mg PO QD or 10 mg PO QD (in postmenopausal women not receiving estrogen) Osteoporosis prophylaxis 5 mg PO QD or 35 mg PO q week	Osteoporosis 10 mg/day or 70 mg/week Glucocorticoid-induced osteoporosis 5 mg/day or 10 mg/day (in postmenopausal women not receiving estrogen) Osteoporosis prophylaxis 5 mg/day or 35 mg/week
Fosamax [®] Plus D (alendronate/ cholecalciferol)	Osteoporosis 70 mg alendronate/2,800 units cholecalciferol or 70 mg alendronate/5,600 units cholecalciferol PO q week	Osteoporosis 70 mg alendronate/5,600 units cholecalciferol/week
risedronate (Actonel [®] , Atelvia [®])	Osteoporosis (including prophylaxis) 5 mg PO QD or 35 mg PO q week or 75 mg PO QD for 2 consecutive days for 2 doses/month or 150 mg PO q month Glucocorticoid-induced osteoporosis 5 mg PO QD	Osteoporosis (including prophylaxis) 5 mg/day or 35 mg/week or 75 mg/day for 2 days per month or 150 mg/month Glucocorticoid-induced osteoporosis 5 mg/day
zoledronic acid (Reclast [®])	Postmenopausal osteoporosis, men with osteoporosis, glucocorticoid- induced osteoporosis 5 mg IV q year Postmenopausal osteoporosis prophylaxis 5 mg IV q 2 years	Postmenopausal osteoporosis, men with osteoporosis, glucocorticoid-induced osteoporosis 5 mg/year Postmenopausal osteoporosis prophylaxis 5 mg/2 years

CLINICAL POLICY
Teriparatide

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
ibandronate (Boniva®)	Postmenopausal osteoporosis 150 mg PO q month or 3 mg IV every 3 months	150 mg/month or 3 mg/3 months
	Postmenopausal osteoporosis prophylaxis 150 mg PO q month	

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: General Information

- The World Health Organization uses the following classifications for osteoporosis and osteopenia:

Category	T-score
Normal	-1.0 or above
Low bone mass (osteopenia)	Between -1.0 and -2.5
Osteoporosis	-2.5 or below

- Men with hypogonadal osteoporosis are defined as those who are receiving testosterone therapy but remain at high risk for fracture, or those who have a contraindication to testosterone therapy.
- Sustained systemic glucocorticoid therapy is defined as a daily dosage equivalent to > 5 mg of prednisone for > 3 months.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Osteoporosis	20 mcg SC QD	20 mcg/day for up to 2 years cumulative use of PTH analogs per lifetime

VI. Product Availability

Multi-dose prefilled pen (2.4 mL): 28 daily doses of 20 mcg

VII. References

- Forteo Prescribing Information. Indianapolis, IN: Eli Lilly and Company; October 2016. Available at <http://www.forteo.com>. Accessed November 8, 2017.
- National Osteoporosis Foundation Clinician’s Guide to Prevention and Treatment of Osteoporosis. Available at: <http://nof.org/files/nof/public/content/file/2791/upload/919.pdf>. Accessed November 9, 2017.
- Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. *Endocr Pract* 2010;16(Suppl 3):1-37.
- Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2017. URL: <http://www.clinicalpharmacology.com>.

CLINICAL POLICY
Teriparatide

5. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. *Arthritis Rheumatol.* 2017; 69(8): 1521-1537.
6. Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guidelines. *J Clin Endocrinol Metab* 2012;97(6):1802-1822.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J3110	Injection, teriparatide, 10 mcg

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy split from CP.PHAR.20.Osteoporosis Injection Therapy and converted to new template. Requests for documentation removed. Criteria: For men with osteoporosis- criteria changed to require testosterone only for hypogonadal rather than primary osteoporosis, and removed required year-long testosterone therapy prior to Forteo. Removed the expected 12-month duration criteria as anti-resorptive therapy is recommended at any glucocorticoid duration; added “at femoral neck or spine” to T score. Removed requirement that must be over 50 in cases where the osteoporosis diagnosis relies on history of an osteoporotic fracture. Added definition of bisphosphonate trial failure and, if contraindication/intolerance, that it be to one of the two oral drugs listed and to Reclast. Calcium/vitamin D requirement language edited to be less specific. Shortened approval durations to 6 months.	02.16	03.16
Age requirement modified to apply to pediatric members with open epiphyses. Added “at total hip” to T score. Added that osteoporotic fracture should be confirmed by radiographic imaging. Removed requirement for administration of calcium/vitamin D. Removed conditions representing potential contraindications to therapy. Added dose to continued therapy. Added requirement for positive response to therapy.	02.17	03.17
Added preferencing for Tymlos in postmenopausal osteoporosis based on SDC decision. Added lifetime	11.01.17	

CLINICAL POLICY
Teriparatide

Reviews, Revisions, and Approvals	Date	P&T Approval Date
limitation criteria for parathyroid hormone analog per previously approved clinical guidance		
1Q18 annual review: <ul style="list-style-type: none"> • Policies combined for commercial and Medicaid. • Converted to new template • Removed criteria for evidence of diagnosis. Removed member characteristic requirements for gender and type of osteoporosis. • Modified age requirement. Modified criteria to add specialist requirement or trial and failure of a bisphosphonate (alendronate is preferred). Removed definition of treatment failure. • Removed requirement regarding admin of last dose of Reclast. • Modified approval duration to 6 months (initial) and 12 months (continuation). • References reviewed and updated. 	11.09.17	02.18

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a

CLINICAL POLICY

Teriparatide

discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

For Health Insurance Marketplace members, when applicable, this policy applies only when the prescribed agent is on your health plan approved formulary. Request for non-formulary drugs must be reviewed using the formulary exception policy.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.